Crinetics Pharmaceuticals
Biopharmaceutical company focused on discovery, development, and commercialization of small-molecule therapies for endocrine and endocrine-related diseases. Internal R&D emphasizes GPCR-targeted, non-peptide small molecules and targeted delivery approaches; clinical development spans Phase 1–3 programs and regulatory submissions in multiple regions. The company integrates patient insights into trial design and operates commercialization activities in the U.S. and Europe.
Industries
Nr. of Employees
large (251-1000)
Crinetics Pharmaceuticals
Patents
Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US-12492181-B2
View DetailsSpirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US-12466829-B2
View Details
Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US-12492181-B2
View DetailsSpirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US-12466829-B2
View DetailsProducts
Oral SST2 receptor agonist for acromegaly and NET-related carcinoid syndrome (paltusotine)
A once-daily, orally administered, non-peptide, selective somatostatin receptor subtype 2 agonist developed for treatment of acromegaly and investigated for carcinoid syndrome in neuroendocrine tumors.
Oral MC2R (ACTH receptor) antagonist for ACTH-driven adrenal disease (atumelnant)
An investigational once-daily, oral melanocortin type 2 receptor antagonist designed to block ACTH activity at the adrenal cortex; developed for congenital adrenal hyperplasia and ACTH‑dependent Cushing’s syndrome.
Non-peptide drug conjugate targeting SST2-expressing tumors (CRN09682)
A targeted small-molecule drug conjugate designed to selectively deliver a cytotoxic payload to SST2-expressing neuroendocrine and other solid tumors; progressed toward a Phase 1 clinical study.
Oral SST2 receptor agonist for acromegaly and NET-related carcinoid syndrome (paltusotine)
A once-daily, orally administered, non-peptide, selective somatostatin receptor subtype 2 agonist developed for treatment of acromegaly and investigated for carcinoid syndrome in neuroendocrine tumors.
Oral MC2R (ACTH receptor) antagonist for ACTH-driven adrenal disease (atumelnant)
An investigational once-daily, oral melanocortin type 2 receptor antagonist designed to block ACTH activity at the adrenal cortex; developed for congenital adrenal hyperplasia and ACTH‑dependent Cushing’s syndrome.
Non-peptide drug conjugate targeting SST2-expressing tumors (CRN09682)
A targeted small-molecule drug conjugate designed to selectively deliver a cytotoxic payload to SST2-expressing neuroendocrine and other solid tumors; progressed toward a Phase 1 clinical study.
Services
Programs to support patient education, testing access, and post-approval support across endocrine indications (example: patient outreach and testing pathways).
Business development and licensing of programs and technologies both inbound and outbound to accelerate development and commercialization.
Programs to support patient education, testing access, and post-approval support across endocrine indications (example: patient outreach and testing pathways).
Business development and licensing of programs and technologies both inbound and outbound to accelerate development and commercialization.
Expertise Areas
- Endocrinology-focused drug discovery
- GPCR-targeted therapeutics
- Small-molecule oral therapeutic development
- Targeted payload delivery for oncology
Key Technologies
- Small-molecule GPCR modulators
- Oral receptor agonist/antagonist chemistry
- Non-peptide drug conjugates (targeted payload delivery)
- Clinical pharmacology and PK/ADME assessment
News & Updates
Perspective on the EC approval of the first once-daily oral therapy for acromegaly in the EU and the company’s European commercialization plans.
An orally administered selective SST2 agonist was approved for treating adults with acromegaly who had inadequate response to surgery or are not surgical candidates.
Perspective on the EC approval of the first once-daily oral therapy for acromegaly in the EU and the company’s European commercialization plans.
An orally administered selective SST2 agonist was approved for treating adults with acromegaly who had inadequate response to surgery or are not surgical candidates.